Evidence map›Paper›PMID 25405614›Full record

Trial reportPloS one2014

Characterization of lung function impairment in adults with bronchiectasis.

Wei-jie Guan, Yong-hua Gao, Gang Xu, Zhi-ya Lin, Yan Tang, Hui-min Li, Zhi-min Lin, Jin-ping Zheng, Rong-chang Chen, Nan-shan Zhong

2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01761214 naunknown statusnot on this map

Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis

TypeinterventionalSponsorGuangzhou Institute of Respiratory DiseaseRan2012 to 2023Enrolled80ConditionsBronchiectasisArmsFluroquinolones, Beta-lactamase inhibitor
NCT02765295 naunknown statusnot on this mapstarted 2016, after this paper: background citation

Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis (HYBRID): A Randomized, Multi-center, Double-blind, Parallel-group Study

TypeinterventionalSponsorGuangzhou Institute of Respiratory DiseaseRan2016 to 2021Enrolled120ConditionsBronchiectasis, Acute Exacerbation of Bronchiectasis, Oxidative StressArmsmedical ultrasonic hydrogen/oxygen nebulizer (MUNHO), Medical molecular mesh oxygen generator
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Inhaled corticosteroids for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Article
  3. Article
  4. Clinical Impacts ofJournal of clinical medicine · 2024
    Article
  5. Biomarkers in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  6. Bronchiectasis in Asia: a review of current status and challenges.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. The biology of pulmonary exacerbations in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Wei-jie GuanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yong-hua GaoDepartment of Respiratory and Critical Care Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Gang XuDepartment of Geriatrics, Guangzhou First People's Hospital, Guangzhou, Guangdong, China.
Zhi-ya LinState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Yan TangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Hui-min LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Zhi-min LinState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Jin-ping ZhengState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Rong-chang ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Nan-shan ZhongState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
First Affiliated Hospital of Guangzhou Medical University · CNGuangzhou Medical University · CNState Key Laboratory of Respiratory Disease · CNFirst Affiliated Hospital of Zhengzhou University · CN

Funding

Therapeutic Strategy for LAM (Lymphangioleiomyomatosis)UH3TR000961 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI EISSA, N. TONY · 2014 to 2016
$3.0M
Therapeutic Strategy for LAM (Lymphangioleiomyomatosis)UH2TR000961 · NCATS · BAYLOR COLLEGE OF MEDICINE · PI EISSA, N. TONY · 2013 to 2013
$1.3M
NCATS NIH HHS UH2 TR000961NCATS NIH HHS UH3 TR000961
6 · The paper itself

Abstract

backgroundCharacteristics of lung function impairment in bronchiectasis is not fully understood.

objectivesTo determine the factors associated with lung function impairment and to compare changes in spirometry during bronchiectasis exacerbation and convalescence (1 week following 14-day antibiotic therapy).

methodsWe recruited 142 patients with steady-state bronchiectasis, of whom 44 with acute exacerbations in the follow-up were included in subgroup analyses. Baseline measurements consisted of chest high-resolution computed tomography (HRCT), sputum volume, purulence and bacteriology, spirometry and diffusing capacity. Spirometry, but not diffusing capacity, was examined during acute exacerbations and convalescence.

resultsIn the final multivariate models, having bronchiectasis symptoms for 10 years or greater (OR = 4.75, 95%CI: 1.46-15.43, P = 0.01), sputum culture positive for Pseudomonas aeruginosa (OR = 4.93, 95%CI: 1.52-15.94, P<0.01) and HRCT total score being 12 or greater (OR = 7.77, 95%CI: 3.21-18.79, P<0.01) were the major variables associated with FEV1 being 50%pred or less; and the only variable associated with reduced DLCO was 4 or more bronchiectatic lobes (OR = 5.91, 95%CI: 2.20-17.23, P<0.01). Overall differences in FVC and FEV1 during exacerbations and convalescence were significant (P<0.05), whereas changes in other spirometric parameters were less notable. This applied even when stratified by the magnitude of FEV1 and DLCO reduction at baseline.

conclusionSignificant lung function impairment should raise alert of chest HRCT abnormality and sputum culture positive for Pseudomonas aeruginosa, in patients with predominantly mild to moderate steady-state bronchiectasis. Acute exacerbations elicited reductions in FVC and FEV1. Changes of other spirometric parameters were less significant during exacerbations.

trial registrationClinicalTrials.gov NCT01761214.

Indexed as

AdultAnti-Bacterial AgentsBacteriaBacterial LoadBronchiectasisCross-Sectional StudiesDrug Therapy, CombinationFemaleForced Expiratory VolumeHumansLungMaleMiddle AgedMultivariate AnalysisProspective StudiesPseudomonas aeruginosaAnti-Bacterial Agents

Identifiers

PMID25405614
PMCPMC4236163
OpenAlexW1998500870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.